Lung cancer EGFR gene mutation detection project started
March 01, 2017 Source: China Medical News
Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];Aide Bio and Boehringer Ingelheim recently announced that they have signed a cooperation agreement to jointly launch the Aide Bio-Boehringer Ingelheim lung cancer EGFR (Cell Epidermal Growth Factor Receptor) mutation blood test project. The project will focus on the promotion of non-small cell lung cancer EGFR mutation blood test in mainland China, to achieve a blood test for non-small cell lung cancer patients with EGFR gene mutation status, so that more non-small cell lung cancer patients have the opportunity to target drugs from EGFR Benefit from it. The lung cancer blood EGFR mutation detection project will use Aide Bio's latest high-sensitivity detection technology ADx-Super-ARMS developed specifically for blood gene mutation detection.
Studies have shown that the occurrence of a variety of malignant tumors, including lung cancer, may be related to mutations in EGFR. Compared with 10%~15% EGFR mutation rate in Europe and America, the EGFR mutation rate in Chinese non-small cell lung cancer population is as high as 50%. At present, lung cancer treatment has entered the era of precision medicine, that is, by detecting the mutation genes that cause lung cancer, and selecting targeted targeted therapeutic drugs for treatment.
Detection of EGFR mutations can be achieved by both tissue detection and blood testing. Compared with tissue testing, blood testing has unique advantages such as non-invasive, convenient sampling, dynamic detection, and overcoming the influence of tumor heterogeneity on detection, and some advanced patients cannot obtain available tissues. Therefore, the detection of blood EGFR mutation detection and The promotion will enable more patients with non-small cell lung cancer to have access to targeted therapy and realize the transition from non-small cell lung cancer treatment to malignant disease management. At present, blood EGFR mutation detection has not been widely carried out, and there are large differences in detection methods and procedures between different regions and hospitals, which greatly affects the diagnosis and individualized treatment options for patients with non-small cell lung cancer. Through the lung cancer EGFR mutation blood test project, Aide Bio and Boehringer Ingelheim are committed to promoting the standardization and flow of EGFR mutation blood test in the hospital, and finally achieving the goal of popularizing EGFR mutation blood test. At the same time, the two sides will jointly provide training and guidance to laboratory technicians, help improve the detection capacity in the hospital, and promote the clinical popularization of precision medicine in China.
"We are proud of the fact that Aide Biotechnology can provide highly reliable and effective diagnostic products and methods for the clinic. These diagnostic methods will contribute to the development of clinical decision-making and will be critical for the treatment of patients with non-small cell lung cancer. Guiding role.†Dr. Zheng Limou, CEO of Aide Bio, said, “As people's understanding of individualized treatment gradually deepens, the two companies have launched and deepened strategic cooperation in the Chinese market, and jointly committed to standardizing EGFR mutation blood testing in China. The promotion of the market will enable a blood test to detect the EGFR gene mutation status, so that more non-small cell lung cancer patients will have access to targeted therapy for the benefit of more cancer patients."
As a R&D-driven pharmaceutical company, Boehringer Ingelheim is actively developing targeted therapies including biopharmaceutical products and small molecule drugs, involving lung cancer and other areas of cancer treatment with unmet medical needs. Currently, Boehringer Ingelheim has marketed two targeted therapies for the treatment of non-small cell lung cancer worldwide, of which afatinib is an irreversible targeted therapy for EGFR mutations. Compared with the first generation of reversible EGFR targeted therapeutic drugs, afatinib can irreversibly bind to EGFR, thereby achieving the purpose of shutting down the cell signaling pathway and inhibiting tumor growth. A large study showed that afatinib was able to reduce lung cancer progression risk and treatment failure risk by 26% compared with the first generation of reversible EGFR-targeted drug gefitinib; The number of patients treated with Nie was twice as high as that of gefitinib. At present, afatinib has been approved for listing in more than 70 countries and regions around the world. In April 2016, it was granted the priority approval by the State Food and Drug Administration.
Mr. Du Rui, Vice President of Boehringer Ingelheim China Specialized Products Division, said: "Boehringer Ingelheim is committed to the development of breakthrough cancer treatments with the potential to change clinical practice, and lung cancer is a key area of ​​our research and development. Currently, China The detection rate of EGFR gene mutations in patients with non-small cell lung cancer is generally low. We hope to improve the detection rate of EGFR gene mutations by virtue of its accurate, reliable and convenient detection technology in cooperation with Aide Biotechnology, so that more lung cancer patients have the opportunity. Benefit from the treatment of targeted drugs."
Professor Liu Xiaoqing of the All-Army Cancer Center of the 307 Hospital of the People's Liberation Army said: "The cooperation between Aide Bio and Boehringer Ingelheim is not only conducive to promoting the popularization of blood detection EGFR mutation technology, but also to discover more EGFR mutation-positive non-small cell lung cancer. Patients and targeted targeted molecular targeted therapy. The second generation of irreversible EGFR-TKI targeted drug afatinib can further improve the therapeutic efficacy of patients with EGFR mutation-positive lung cancer while ensuring patients' quality of life. To extend its survival." (Ai Wen)
Paddy Sprayer,Farmland Sprayer,Farmland Rice Sprayer,Agricultural Rice Sprayer
Taizhou Yingtian Agricultural Machinery Manufacturing Co., Ltd. , https://www.sakuradaagc.com